61199-35-7

Upstream product

• 15971-92-3 ethyl 3-cyclohexyl-3-oxopropanoate 
• 61199-34-6 5-cyclohexyl-2-methyl-1,2-dihydro-pyrazol-3-one 

Downstream Products

• 132026-58-5 5-chloro-3-cyclohexyl-4-nitro-1-methylpyrazole 
• 132026-71-2 5-Cyclohexyl-2,N³-dimethyl-2H-pyrazole-3,4-diamine 
• 132026-62-1 (5-Cyclohexyl-2-methyl-4-nitro-2H-pyrazol-3-yl)-methyl-amine 
• 61199-36-8 3-chloro-5-cyclohexyl-1,2-dimethylpyrazolium methyl sulfate 

Relevant academic research and scientific papers

Novel Antagonists of Platelet-Activating Factor. 2. Synthesis and Structure-Activity Relationships of Potent and Long-Acting Heterofused Benzodiazepine and Diazepine Derivatives of 2-Methyl-1-phenylimidazopyridine

The optimization of in vitro activty and oral potency and duration of action in vivo is described for three novel structural types of platelet-activating factor (PAF) antagonist: benzodiazepines 5-12 onto which a variety of other heterocyclic rings were fused, pyridodiazepinones 13-26, and pyrazolodiazepinones 27-46.Compounds 5-12 were prepared by elaboration of the benzodiazepine-2-thiones 47 and 48, and 13-46 were prepared by cyclocondensation reactions of a variety of 2,3-diaminopyridine and 4,5-diaminopyrazole derivatives with ethyl 4'-(2-methylimidazopyrid-1-yl)benzoylacetate (53).The presence of imine-enamine tautomerism was observed in certain diazepine derivatives and is discussed.Structure-activity relationships were evaluated where PAF antagonist activity was measured in vitro by determining the concentration of compound (IC50) required to inhibit PAF-induced aggregation of rabbit washed platelets and in vivo by determining the oral dose (ED50) which protected mice from a lethal injection of PAF.In addition, the duration of action in conscious dogs was measured by determining the oral dose of selected compounds required to inhibit completely PAF-induced whole blood aggregation ex vivo.The most potent compound was 1,6,7,8-tetrahydro-1,8-dimethyl-5-pyrid-1-yl)phenyl>-7-oxo-3-(3-pyridyl)pyrazolodiazepine (43, UK-91,473) (IC50=2.4 nM, ED50=0.01 mg/kg po), which was found to be significantly more potent in vivo (murine lethality) than the dihydropyridine PAF antagonist 4-(2-chlorophenyl)-1,4-dihydro-3-(ethoxycarbonyl)-6-methyl-4-pyrid-1-yl)phenyl>-5-pyridine (4, UK-74,505) (ED50=0.26 mg/kg po).Compound 43 also possessed a longer duration of action than compound 4 in the conscious dog at one-fourth of the dose.The crystal structure of compound 43, established by X-ray diffraction, is reported.

Diazepine antiallergy agents

Platelet activating factor antagonists of formula (I), (II) or (III): STR1 where A is optionally substituted benzene, pyridine, naphthalene, quinoline, thiophene, benzothiophene, pyrazole or isothiazole, X is O, S or NH Y is 1,4 phenylene or a group of formula STR2 R1 is H or optionally substituted C1 -C4 alkyl, R2 and R3 are H or C1 -C4 alkyl, B is an optionally fused 5- or 6-membered ring containing nitrogen atoms, Het is an optionally substituted 5-membered heterocyclic ring containing nitrogen or a pyridine ring, the ring optionally being fused to benzene or nitrogen-containing heterocyclic ring.

Novel 1,2-dialkylpyrazolium compounds having 3-(or 3,5-) nitrogen-containing heterocyclic group as herbicides

There are provided 1,2-dialkylpyrazolium compounds having positioned thereon a 3- or 5-substituted nitrogen-containing heterocyclic group or 3,5-disubstituted nitrogen-containing heterocyclic groups as well as a method for preparing the same. There is als

1,2-Dialkyl-3(or 3,5)-N-heterocyclic pyrazolium salts of derivatives thereof as fungicidal agents

There is provided a method for controlling fungi with a fungicidally effective amount of a 1,2-dialkyl-3(or 3,5)-N-heterocyclic pyrazolium salt. There is also provided a method for protecting living plants from attack by fungi through the application to t